Revised Crestor royalties a reprieve for AstraZeneca?
This article was originally published in Scrip
Executive Summary
The originator of Crestor (rosuvastatin), Shionogi, is to modify from the beginning of calendar 2014 its arrangements with global licensee AstraZeneca for royalties paid on the blockbuster cholesterol-lowering drug. The two firms have also agreed to settle arbitration proceedings over how the royalties are calculated.